Biogen’s Phase II Lupus Success Offers An Additional Viable Pipeline Asset
Executive Summary
While Biogen is seeking to diversify its R&D efforts, unexpected good data in two forms of lupus make internally discovered BIIB059 a viable asset to take forward, although Phase III plans are not set.
You may also be interested in...
Aurinia Closing In On Lupus Nephritis With Voclosporin
Canada’s Aurinia Pharmaceuticals expects to file a US NDA in the first half of next year on the use of its next-generation calcineurin inhibitor, voclosporin, in lupus nephritis, a condition with no approved therapies.
AstraZeneca Closer To Filing Anifrolumab For Lupus
Having recovered from a late-stage fail last year, AstraZeneca has fleshed out results from a positive second Phase III trial of anifrolumab which it hopes will be the second new lupus treatment to hit the market in 60 years.
IPF Failure Sets Back Biogen’s Diversification Efforts
The company has discontinued a Phase II trial for BG00011, which was acquired in its 2012 Stromedix purchase, due to safety issues.